Home › Liver Cancer (Hepatocellular Carcinoma) › NCT07303712

Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization and Assessment of Treatment Response After Y90 Radioembolization: A Pilot Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Age \> or = 18 years
2. HCC confirmed on imaging, BCLC stage 0, A, B, or C
3. Transarterial Y90 radioembolization approved by multidisciplinary tumor board -

Exclusion Criteria:

1. Not eligible for Y90 procedure
2. Prior surgery or ablation on indicated tumors
3. Patient unable to complete the follow up visits required for clinical care or research -

About the study

The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).

Sponsor: Palo Alto Veterans Institute for Research · Participants: 12 · Started: Aug 1, 2024

Contact the study team

• Sirish Kishore, MD · Phone: 650-493-5000
• Luisa Manfredi, MPH · Phone: 650-493-5000

Official record on ClinicalTrials.gov — NCT07303712

Locations in the U.S.

Conditions

• Liver Cancer (Hepatocellular Carcinoma)
• Circulating Neoplastic Cells

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.